Switching from Warfarin to Apixaban for DVT: Dosing
When switching from warfarin to apixaban (Eliquis) for DVT treatment, discontinue warfarin and start apixaban 10 mg orally twice daily once the INR falls below 2.0, continuing this dose for 7 days before reducing to 5 mg twice daily. 1
Transition Protocol
The FDA-approved transition strategy is straightforward 1:
- Stop warfarin when INR monitoring shows a value below 2.0
- Immediately begin apixaban at the treatment dose—no bridging with parenteral anticoagulation is needed
- Do not wait for the INR to normalize completely; INR < 2.0 is the threshold
Apixaban Dosing Regimen for DVT
The treatment course follows a two-phase approach 2, 1:
Initial Phase (Days 1-7):
- 10 mg orally twice daily for exactly 7 days
Maintenance Phase (Day 8 onward):
- 5 mg orally twice daily for the duration of treatment
This regimen is supported by multiple guidelines 3, 2, 4, 2 and represents the only DOAC that does not require initial parenteral anticoagulation lead-in, making the transition from warfarin particularly seamless.
Critical Timing Considerations
The INR threshold of 2.0 is crucial 1. Starting apixaban while the INR remains elevated (≥2.0) creates excessive anticoagulation overlap and increases bleeding risk. Conversely, waiting too long after warfarin discontinuation without starting apixaban creates a gap in anticoagulation coverage.
Common pitfall: Some clinicians mistakenly use the atrial fibrillation dose (5 mg twice daily) when switching patients with DVT. This is incorrect—DVT treatment requires the higher initial dose of 10 mg twice daily for the first week 2, 1.
Dose Adjustments
Renal function matters: If creatinine clearance is significantly impaired, review the prescribing information, though apixaban has minimal renal elimination (27%) compared to other DOACs 5. No routine dose reduction is specified for DVT treatment based solely on renal function in the FDA label 1.
Drug interactions: If the patient is taking combined P-glycoprotein and strong CYP3A4 inhibitors (ketoconazole, itraconazole, ritonavir), reduce the apixaban dose by 50% 1. This means 5 mg twice daily during the initial phase instead of 10 mg.
Why This Approach Works
Unlike dabigatran and edoxaban, which require 5-10 days of parenteral anticoagulation before initiation 2, apixaban's pharmacokinetic profile allows direct transition from warfarin. The 10 mg twice daily dosing for 7 days provides adequate anticoagulation intensity during the critical early treatment period when VTE recurrence risk is highest 6, 7.
Recent real-world evidence confirms that using the full 7-day lead-in period of 10 mg twice daily, even after parenteral anticoagulation, is associated with lower VTE recurrence rates compared to shortened regimens 8, 9.
Extended Treatment Considerations
After completing at least 6 months of treatment at 5 mg twice daily, consider reducing to 2.5 mg twice daily for extended secondary prevention if continued anticoagulation is indicated 2, 7. This lower dose maintains efficacy for preventing recurrent VTE while potentially reducing bleeding risk.